The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” ...

The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...

Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 ...

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...